Miguel Forte – CEO, Bone Therapeutics, Belgium
Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes…
Address: Haasrode Researchpark 1724
Romeinse straat 12 bus 2
3001 Leuven
Belgium
Tel: +32 (0) 16 39 60 60
TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programs. The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched across Europe. TiGenix’s adipose derived allogeneic stem cell platform has been extensively validated. The company has initiated a Phase III clinical trial to treat complex perianal fistulas in patients with Crohn’s disease, has a Phase IIa trial in rheumatoid arthritis ongoing, and has successfully concluded a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
ChondroCelect® for cartilage regeneration in the knee is an implantation suspension of characterised viable autologous (from the patient her- or himself) cartilage cells. The product is administered to patients in an autologous chondrocyte implantation procedure known as Characterised Chondrocyte Implantation (CCI), a surgical procedure to treat cartilage defects, in conjunction with debridement (preparation of the defect bed), a physical seal of the lesion (placement of a biological membrane, preferentially a collagen membrane) and rehabilitation.
ChondroCelect is the first cell-based product to successfully complete the entire development track from research to clinical development to approval by the European Medicines Agency as an Advanced Medicinal Therapy Product in October, 2009. ChondroCelect is commercially available in Belgium, the Netherlands, Luxemburg, Germany, the United Kingdom, Finland, and Spain.
Moreover, TiGenix uniquely combines early stage revenues from its ChondroCelect sales with the mid- to long-term commercial potential from its expanded adipose stem cell pipeline.
Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes…
Brigitte Nolet, country manager of Roche for Belgium and Luxembourg, speaks about her transition to the Belgian market and her priorities for leading the affiliate. Nolet goes on the elaborate…
Jean Nève and Fabrice Peters, president and general coordinator of the Belgian Superior Health Council (SHC), introduce the organization, elaborate on its role in helping guide the country’s healthcare policy,…
Bertrand Duquesne, managing director of Boiron Belgium, elaborates on the challenges being faced by homeopathy manufacturers in western Europe and explains how the company and its peers are create dialogue…
Vincent Verschraegen, country manager of Mylan Belgium and Luxembourg, speaks about his onboarding in the company and what attracted him to join the organization. Verschraegen also discusses Mylan’s evolution from…
PDC*Line Pharma’s Eric Halioua introduces the Belgian immuno-oncology biotech, its clinical-stage assets, the impact of the firm’s collaboration with Korean LG Chem, and future internationalisation strategies. As a multicultural…
Miranda Heining, general manager of Fresenius Kabi for Belgium and the Netherlands, speaks about the career path that led her to join the pharma industry and lead the affiliate, her…
Christos Andriopoulos, managing director of Merck, speaks about his experience transitioning from global operations to leading a country subsidiary. Andriopoulos goes on to explain the company’s unique positioning as an…
Fréderic Covemaeker, general manager of Nordic Pharma Belgium, introduces the Belgian affiliate which he established himself in 2008 and elaborates on the next stage of development for operations as Nordic…
Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to…
Xavier De Cuyper introduces the Federal Agency for Medicines & Health Products (FAMHP) and the essential role it plays in Belgium’s healthcare regulatory framework since being founded in 2007. De…
Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights into the healthcare and research dynamics surrounding neurological diseases. Depondt…
See our Cookie Privacy Policy Here